title: The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance.
abstract: The IL-13Ralpha2 receptor is a high affinity receptor for IL-13 that is used only by IL-13 and is quite distinct from the well known IL-13Ralpha1 receptor that IL-13 shares with IL-4. It was widely considered to be a secreted receptor that is devoid of signaling activity and functional only as a decoy receptor that retarded signaling via IL-13Ralpha1. In recent studies, however, it was shown to be capable of robust signaling that results in production of TGF-beta1 and through the latter cytokine, the induction of fibrosis occuring in various experimental inflammatory states. Thus, in initial studies, IL-13 signaling via IL-13Ralpha2 was shown to play an important role in the fibrosis developing in both oxazolone colitis and bleomycin-induced pulmonary fibrosis; later, it was also shown to be critical to the development of fibrosis in a model of chronic colitis induced by trinitrobenzene sulphonic acid (TNBS). These studies suggest that blockade of IL-13 or IL-13Ralpha2 signaling might be an excellent target for the prevention of inflammation-associated fibrosis. A second role of IL-13 signaling via IL-13Ralpha2 is in tumor immune surveillance. Thus, in the relevant studies it was shown that NKT cells stimulated by tumor antigens produce IL-13 that then acts on Gr-1 cells to induce TGF-beta1; the latter then inhibits CD8+ T cells engaged in tumor immune surveillance; in effect, then, receptor signaling favors tumor growth. In addition to its signaling function and the induction of TGF-beta1, IL-13Ralpha2 also influences IL-13Ralpha1 signaling in complex ways; thus, IL-13Ralpha2 emerges as a important component of IL-13 signaling, not only in its own right but also in its possible effect on its companion receptor.
authors.affiliation: Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Warren
authors.initials: W
authors.lastname: Strober
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kitani
authors.forename: Stefan
authors.initials: S
authors.lastname: Fichtner-Feigl
authors.forename: Ivan J
authors.initials: IJ
authors.lastname: Fuss
mesh_terms: D000818:Animals; D005355:Fibrosis; D041981:Gastrointestinal Tract / Q000473:pathology*; D006801:Humans; D007157:Immunologic Surveillance / Q000276:immunology*; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D015398:Signal Transduction / Q000276:immunology*
chemical_list: D053663:Interleukin-13 Receptor alpha2 Subunit
references.citation: J Immunother. 2005 May-Jun;28(3):193-202
references.pmid: 15838375
references.citation: J Allergy Clin Immunol. 2006 Oct;118(4):858-65
references.pmid: 17030238
references.citation: J Biol Chem. 1996 Nov 15;271(46):29265-70
references.pmid: 8910586
references.citation: J Immunol. 2007 May 1;178(9):5859-70
references.pmid: 17442970
references.citation: Cancer Res. 2002 Feb 15;62(4):1103-9
references.pmid: 11861389
references.citation: J Immunol. 2006 Dec 1;177(11):7905-12
references.pmid: 17114462
references.citation: J Allergy Clin Immunol. 2008 Sep;122(3):625-32
references.pmid: 18694590
references.citation: J Exp Med. 2003 Dec 1;198(11):1741-52
references.pmid: 14657224
references.citation: J Immunol. 2006 Jun 15;176(12):7495-501
references.pmid: 16751396
references.citation: J Exp Med. 1998 Nov 16;188(10):1929-39
references.pmid: 9815270
references.citation: Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2004 Jun;22(3):154-6
references.pmid: 15597710
references.citation: J Immunol. 2004 Sep 15;173(6):4020-9
references.pmid: 15356151
references.citation: J Biol Chem. 2007 Apr 6;282(14):10172-9
references.pmid: 17287216
references.citation: Cancer Res. 2008 May 1;68(9):3467-75
references.pmid: 18451175
references.citation: Mol Ther. 2002 Aug;6(2):219-26
references.pmid: 12161188
references.citation: J Exp Med. 2003 Mar 17;197(6):703-9
references.pmid: 12642602
references.citation: Int J Cancer. 2005 Mar 10;114(1):80-7
references.pmid: 15523692
references.citation: Cancer Res. 2005 Apr 1;65(7):2956-63
references.pmid: 15805299
references.citation: J Exp Med. 2005 Dec 19;202(12):1627-33
references.pmid: 16365146
references.citation: Nat Med. 2006 Jan;12(1):99-106
references.pmid: 16327802
references.citation: Immunity. 2002 Nov;17(5):629-38
references.pmid: 12433369
references.citation: J Exp Med. 2003 Mar 17;197(6):687-701
references.pmid: 12642601
references.citation: Am J Respir Cell Mol Biol. 2002 Oct;27(4):419-27
references.pmid: 12356575
references.citation: J Tongji Med Univ. 2000;20(4):320-1, 329
references.pmid: 12840923
references.citation: J Exp Med. 1990 Mar 1;171(3):861-73
references.pmid: 2307934
references.citation: Cancer Res. 2006 Apr 1;66(7):3869-75
references.pmid: 16585215
references.citation: J Immunol. 2000 May 15;164(10):5337-43
references.pmid: 10799896
references.citation: Mem Inst Oswaldo Cruz. 2006 Sep;101 Suppl 1:353-4
references.pmid: 17308796
references.citation: J Immunol. 1998 Sep 1;161(5):2317-24
references.pmid: 9725226
references.citation: Clin Exp Allergy. 2008 Apr;38(4):594-601
references.pmid: 18307523
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6231-8
references.pmid: 15448012
references.citation: Cytokine. 2003 Dec 21;24(6):293-303
references.pmid: 14609571
references.citation: J Immunol. 2008 Jan 1;180(1):522-9
references.pmid: 18097054
references.citation: Blood. 2001 May 1;97(9):2673-9
references.pmid: 11313257
references.citation: J Exp Med. 2001 Sep 17;194(6):809-21
references.pmid: 11560996